Get started

Financials · KROS

Keros Therapeutics Inc. (KROS) financials

For fiscal 2025 (ended Dec 31, 2025), Keros Therapeutics Inc. reported $244.06M of revenue and $87.01M of net income.

Revenue, FY2025
$244.06M
Revenue growth, YoY
+6775.0%
Net income, FY2025
$87.01M
Net margin
35.7%
Free cash flow, FY2025
$105.95M
EPS, diluted, FY2025
$2.30
Cash
$259.46M
P/E
2.07
P/S
0.74
Market cap
$180.0M
Annual revenue$244.06M
FY2019FY2025
Annual net income$87.01M
FY2019FY2025
Annual free cash flow$105.95M
FY2019FY2025

KROS revenue and earnings growth

KROS revenueQ3 2026$40.01M

Quarter YoY
+180.5%
FY YoY
69x

KROS revenue was $40.01M in fiscal Q3 2026 (ended Sep 30, 2026), up 180.5% from a year earlier. For the full fiscal 2025 it was $244.06M, up about 69-fold from fiscal 2024. Fiscal 2025 is the highest of the 7 fiscal years on file.

KROS net incomeQ3 2026$14.15M

KROS net income was $14.15M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$7.28M a year earlier. For the full fiscal 2025 it was $87.01M, compared with -$187.35M in fiscal 2024. Fiscal 2025 is the highest of the 7 fiscal years on file.

KROS EPSQ3 2026$0.70

KROS diluted EPS was $0.70 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was $2.30, compared with -$5.00 in fiscal 2024.

KROS free cash flowQ3 2026$3.33M

Quarter YoY
+6.9%

KROS free cash flow was $3.33M in fiscal Q3 2026 (ended Sep 30, 2026), up 6.9% from a year earlier. For the full fiscal 2025 it was $105.95M, compared with -$162.80M in fiscal 2024. Fiscal 2025 is the highest of the 7 fiscal years on file.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$244.06M$3.55M$151.0K$0$20.10M$0$10.00M
Research and development$129.64M$173.63M$135.26M$87.27M$55.14M$33.86M$17.38M
Selling, general and admin$46.85M$40.75M$34.83M$27.52M$21.33M$12.80M$3.18M
Operating income$67.57M-$210.83M-$169.94M-$114.79M-$56.37M-$46.66M-$10.56M
Pre-tax income$91.90M-$187.05M-$152.99M-$104.68M-$56.73M-$45.53M-$12.34M
Income tax$4.88M$300.0K$0$0$2.01M-$172.0K$0
Net income$87.01M-$187.35M-$152.99M-$104.68M-$58.74M-$45.36M-$12.34M
EPS, basic$2.34-$5.00-$5.20-$4.15-$2.52-$2.93-$6.08
EPS, diluted$2.30-$5.00-$5.20-$4.15-$2.52-$2.93-$6.08
Diluted shares37.9M37.4M29.4M25.2M23.3M15.5M2.3M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$287.42M$561.38M$332.36M$279.05M$231.37M$265.99M$7.13M
Receivables$3.57M$2.74M$143.0K$0$18.00M$0-
Current assets$315.43M$588.89M$347.29M$285.77M$251.44M$267.73M$8.93M
Total assets$338.02M$615.89M$370.02M$306.78M$255.25M$269.44M$10.96M
Current liabilities$20.41M$27.45M$24.37M$16.55M$11.85M$7.18M$4.49M
Total liabilities$34.89M$44.33M$37.81M$29.36M$12.08M$7.72M$10.46M
Shareholders' equity$303.13M$571.55M$332.21M$277.42M$243.17M$261.72M-$19.45M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow$107.50M-$160.87M-$124.51M-$70.06M-$62.15M-$36.89M-$16.00M
Capital expenditures$1.55M$1.93M$2.46M$1.24M$1.02M$294.0K$271.0K
Free cash flow$105.95M-$162.80M-$126.97M-$71.30M-$63.17M-$37.19M-$16.27M
Investing cash flow-$1.55M-$1.93M-$2.46M-$1.24M-$1.02M-$294.0K-$271.0K
Financing cash flow-$378.47M$391.82M$178.96M$120.31M$28.55M$296.04M$14.0K
Share repurchases$375.00M$0-----
Stock-based compensation$28.70M$34.87M$28.76M$18.68M$11.72M$4.10M$59.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY6775.0%2251.0%--100.0%--100.0%-
Operating margin27.7%-5939.0%-112543.7%--280.5%--105.6%
Net margin35.7%-5277.5%-101319.2%--292.3%--123.4%
Free cash flow margin43.4%-4585.9%-84087.4%--314.3%--162.7%
Return on equity28.7%-32.8%-46.1%-37.7%-24.2%-17.3%-
Return on assets25.7%-30.4%-41.3%-34.1%-23.0%-16.8%-112.6%
Current ratio15.4521.4514.2517.2721.2337.271.99

Source: XBRL data Keros Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

KROS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
KROS$244.06M+6775.0%$87.01M35.7%$180.0M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

KROS FAQ

8 questions
  • What is KROS revenue?
    Keros Therapeutics Inc. (KROS) reported $244.06M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 6775.0% from the year before.
  • Is KROS profitable?
    Yes. Keros Therapeutics Inc. earned $87.01M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 35.7%.
  • How much cash and debt does KROS have?
    Keros Therapeutics Inc. reported $259.46M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is KROS revenue growing?
    Keros Therapeutics Inc.'s revenue changed 69x in fiscal 2025, to $244.06M.
  • What is KROS free cash flow?
    Keros Therapeutics Inc. generated $105.95M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of $107.50M less capital expenditures.
  • What is KROS earnings per share?
    Diluted earnings per share were $2.30 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.
  • When did KROS last report financial results?
    The latest statements here come from Keros Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this KROS financial data come from?
    Quantisnow builds these statements from the structured XBRL data Keros Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.